These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35324657)

  • 21. Antinociceptive Effects of Transcytosed Botulinum Neurotoxin Type A on Trigeminal Nociception in Rats.
    Kim HJ; Lee GW; Kim MJ; Yang KY; Kim ST; Bae YC; Ahn DK
    Korean J Physiol Pharmacol; 2015 Jul; 19(4):349-55. PubMed ID: 26170739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin A alleviates orofacial nociception induced by orthodontic tooth movement through nociceptin/orphanin-FQ pathway in rats.
    Lyu J; Wen J; Guo R; Zhu Y; Liang H; Gao M; Wang H; Lai W; Long H
    Arch Oral Biol; 2020 Sep; 117():104817. PubMed ID: 32603879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrathecal administration of botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis.
    Coelho A; Oliveira R; Rossetto O; Cruz CD; Cruz F; Avelino A
    Eur J Pain; 2014 Nov; 18(10):1480-9. PubMed ID: 24756904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain.
    Fan C; Chu X; Wang L; Shi H; Li T
    Toxicon; 2017 Jul; 133():116-122. PubMed ID: 28478059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What have we learned about antinociceptive effect of botulinum toxin type A from mirror-image pain models?
    Drinovac Vlah V; Bach-Rojecky L
    Toxicon; 2020 Oct; 185():164-173. PubMed ID: 32698026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.
    Favre-Guilmard C; Auguet M; Chabrier PE
    Eur J Pharmacol; 2009 Sep; 617(1-3):48-53. PubMed ID: 19576881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum Toxin and Pain.
    Lacković Z
    Handb Exp Pharmacol; 2021; 263():251-264. PubMed ID: 32016565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antinociceptive Effects of Botulinum Toxin Type A on Trigeminal Neuropathic Pain.
    Yang KY; Kim MJ; Ju JS; Park SK; Lee CG; Kim ST; Bae YC; Ahn DK
    J Dent Res; 2016 Sep; 95(10):1183-90. PubMed ID: 27418174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgia.
    Wu C; Xie N; Lian Y; Xu H; Chen C; Zheng Y; Chen Y; Zhang H
    Springerplus; 2016; 5():431. PubMed ID: 27104119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice.
    Abrahão Cunha TC; Gontijo Couto AC; Januzzi E; Rosa Ferraz Gonçalves RT; Silva G; Silva CR
    Toxicon X; 2021 Nov; 12():100083. PubMed ID: 34527897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of central opioid on the antinociceptive effect of sulfated polysaccharide from the red seaweed Solieria filiformis in induced temporomandibular joint pain.
    Araújo IW; Chaves HV; Pachêco JM; Val DR; Vieira LV; Santos R; Freitas RS; Rivanor RL; Monteiro VS; Clemente-Napimoga JT; Bezerra MM; Benevides NM
    Int Immunopharmacol; 2017 Mar; 44():160-167. PubMed ID: 28107753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A.
    Mustafa G; Anderson EM; Bokrand-Donatelli Y; Neubert JK; Caudle RM
    Pain; 2013 Nov; 154(11):2547-2553. PubMed ID: 23933181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes.
    Marinelli S; Vacca V; Ricordy R; Uggenti C; Tata AM; Luvisetto S; Pavone F
    PLoS One; 2012; 7(10):e47977. PubMed ID: 23110146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents.
    Ramachandran R; Lam C; Yaksh TL
    Neurobiol Dis; 2015 Jul; 79():111-22. PubMed ID: 25958249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential.
    Meng J; Ovsepian SV; Wang J; Pickering M; Sasse A; Aoki KR; Lawrence GW; Dolly JO
    J Neurosci; 2009 Apr; 29(15):4981-92. PubMed ID: 19369567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence on botulinum toxin in selected disorders.
    Zakin E; Simpson D
    Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain.
    Mahowald ML; Krug HE; Singh JA; Dykstra D
    Toxicon; 2009 Oct; 54(5):658-67. PubMed ID: 19351542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin type A ameliorates adjuvant-arthritis pain by inhibiting microglial activation-mediated neuroinflammation and intracellular molecular signaling.
    Shi X; Gao C; Wang L; Chu X; Shi Q; Yang H; Li T
    Toxicon; 2020 Apr; 178():33-40. PubMed ID: 32250746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for central antispastic effect of botulinum toxin type A.
    Matak I
    Br J Pharmacol; 2020 Jan; 177(1):65-76. PubMed ID: 31444910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.